ASP1517 Phase 3 Clinical Trial; A Multi-center, Randomized, Open-label, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Non-dialysis Chronic Kidney Disease Patients With Anemia
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Roxadustat (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 27 May 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
- 27 May 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
- 27 Feb 2018 According to a FibroGen media release, data readout anticipated in the first quarter of 2018.